Patients with type 2 diabetes (T2D) are at increased risk of chronic kidney disease (CKD) or end-stage renal disease (ESRD). We estimated the prevalence and incidence of CKD/ESRD among adults with incident T2D within a U.S. integrated healthcare system.

Incident T2D between 2003-2014 was identified based on a validated algorithm. CKD was defined as eGFR <60 ml/min/1.73m2 on ≥2 occasions 90 days apart and ESRD as initiation of chronic dialysis or renal transplant. Prevalence of CKD/ESRD was evaluated for the 2 years prior and 6 months after T2D diagnosis (index). Incidence of CKD/ESRD was evaluated from 6 months after index through 2018. Multivariable Cox proportional hazards models were used to study factors associated with CKD incidence.

We identified 135,199 incident T2D [mean age 58 years, 48% women, 36% White, 35% Hispanic, 12% Black, 13% Asian]. Median follow up was 6 years. Prevalence of CKD and ESRD was 12.3% and 0.2%, respectively. Median (IQR) eGFR closest to index was 86 (70-101) ml/min/1.73m2. The CKD/ESRD incidence rates decreased for recent diagnoses (2-year CKD incidence: 35.4 vs. 16.6 per 1000 person-years for those diagnosed in 2003-2004 vs. 2013-2014) (Table). Older age, white race, lower eGFR, higher A1c, and hypertension were associated with increased CKD incidence.

Though incidence rates are improving, a significant proportion of patients had reduced eGFR including CKD/ESRD at diagnosis.

Disclosure

J. An: Research Support; Self; Merck & Co., Inc., Novartis AG. G.A. Nichols: Research Support; Self; Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Merck & Co., Inc. L. Qian: None. Z. Li: None. M.A. Munis: None. R. Wei: None. T. Harrison: None. T. Weiss: Employee; Self; Merck & Co., Inc. S. Rajpathak: Employee; Self; Menarini Group. K. Reynolds: Research Support; Self; CSL Behring, Merck & Co., Inc., National Institutes of Health, Novartis Pharmaceuticals Corporation.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.